Literature DB >> 18058330

Drugs as CYP3A probes, inducers, and inhibitors.

Yi-Tong Liu1, Hai-Ping Hao, Chang-Xiao Liu, Guang-Ji Wang, Hong-Guang Xie.   

Abstract

Human cytochrome P450 (CYP) 3A subfamily members (mainly CYP3A4 and CYP3A5) mediate the metabolism of approximately half all marketed drugs and thus play a critical role in the drug metabolism. A huge number of studies on CYP3A-mediated drug metabolism in humans have demonstrated that CYP3A activity exhibits marked ethnic and individual variability, in part because of altered levels of CYP3A4 expression by various environmental factors and functionally important polymorphisms present in CYP3A5 gene. Accumulating evidence has revealed that CYP3A4 and CYP3A5 have a significant overlapping in their substrate specificity, inducers and inhibitors. Therefore, it is difficult to define their respective contribution to drug metabolism and drug-drug interactions. Furthermore, P-glycoprotein and CYP3A are frequently co-expressed in the same cells and share a large number of substrates and modulators. The disposition of such drugs is thus affected by both metabolism and transport. In this review, we systematically summarized the frequently used CYP3A probe drugs, inducers and inhibitors, and evaluated their current status in drug development and research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18058330     DOI: 10.1080/03602530701690374

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  42 in total

1.  Evaluation of CYP3A4 inhibition and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells.

Authors:  Yitong Liu; Thomas J Flynn; Menghang Xia; Paddy L Wiesenfeld; Martine S Ferguson
Journal:  Cell Biol Toxicol       Date:  2015-09-16       Impact factor: 6.691

Review 2.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

3.  Emergence delirium with transient associative agnosia and expressive aphasia reversed by flumazenil in a pediatric patient.

Authors:  Julie K Drobish; Max B Kelz; Patricia M DiPuppo; Scott D Cook-Sather
Journal:  A A Case Rep       Date:  2015-06-01

Review 4.  Drug interactions--principles, examples and clinical consequences.

Authors:  Ingolf Cascorbi
Journal:  Dtsch Arztebl Int       Date:  2012-08-20       Impact factor: 5.594

5.  Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

Authors:  E D Kharasch; A Francis; A London; K Frey; T Kim; J Blood
Journal:  Clin Pharmacol Ther       Date:  2011-05-11       Impact factor: 6.875

6.  Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans.

Authors:  Kyoung-Ah Kim; In-Bae Park; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2018-06-13       Impact factor: 2.953

7.  Proximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substrates.

Authors:  Lingtak-Neander Chan; Yvonne S Lin; Jessica C Tay-Sontheimer; Dorothy Trawick; Brant K Oelschlager; David R Flum; Kristen K Patton; Danny D Shen; John R Horn
Journal:  Pharmacotherapy       Date:  2015-03-10       Impact factor: 4.705

8.  Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.

Authors:  E D Kharasch; S Vangveravong; N Buck; A London; T Kim; J Blood; R H Mach
Journal:  Clin Pharmacol Ther       Date:  2011-02-23       Impact factor: 6.875

9.  Prediction of Cytochrome P450 Profiles of Environmental Chemicals with QSAR Models Built from Drug-like Molecules.

Authors:  Hongmao Sun; Henrike Veith; Menghang Xia; Christopher P Austin; Raymond R Tice; Ruili Huang
Journal:  Mol Inform       Date:  2012-10-11       Impact factor: 3.353

10.  Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System.

Authors:  Xiaojing Wang; Minghua Sun; Connie New; Spencer Nam; Wesley P Blackaby; Alastair J Hodges; David Nash; Mizio Matteucci; Joseph P Lyssikatos; Peter W Fan; Suzanne Tay; Jae H Chang
Journal:  ACS Med Chem Lett       Date:  2015-07-12       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.